

Table 1 (online only). Demographics of Cases by Site

	Site 1 N=13	Site 2 N=68	Site 3 N=33	Site 4 N=65	Site 5 N=15	Site 6 N=21	Site 7 N=6	Site 8 N=40	All N=261
Age, years (median, IQR)	3.7 (1.5-9.2)	10.3 (4.2-12.7)	6.5 (2.8-9.8)	6.7 (3.7-11.4)	4.0 (2.2-11.6)	8.3 (3.6-13.0)	7.7 (1.8-11.3)	5.0 (1.9-10.8)	6.8 (2.5-11.8)
BMI ^a , kg/m ² (median, IQR)	18.9 (16.3-32.5)	19.8 (15.0-21.9)	15.9 (13.4-18.4)	17.6 (14.9-24.7)	16.3 (13.4-18.0)	17.3 (16.4-18.1)	18.6 (16.8-19.1)	18.6 (15.9-23.5)	18.1 (15.1-22.7)
Sex, male (n, %)	7 (54)	48 (71)	25 (76)	37 (57)	8 (53)	12 (57)	5 (83)	19 (48)	161 (62)
Race (n, %) *									
Black	4 (57)	57 (86)	12 (50)	43 (72)	2 (15)	7 (35)	2 (50)	14 (40)	141 (62)
White	2 (29)	9 (14)	11 (46)	14 (23)	9 (69)	9 (45)	1 (25)	21 (60)	76 (33)
Asian	1 (14)	0	1 (4)	3 (5)	1 (8)	1 (5)	1 (25)	0	8 (3)
Other	0	0	0	0	1 (8)	3 (15)	0	0	4 (2)
Ethnicity (n, %)									
Hispanic	6 (46)	0	1 (3)	8 (12)	1 (7)	4 (19)	0	0	20 (8)
Non-Hispanic	7 (54)	66 (97)	22 (67)	51 (78)	13 (87)	17 (81)	4 (67)	4 (10)	184 (70)
Unknown	0	2 (3)	10 (30)	6 (9)	1 (7)	0	2 (33)	36 (90)	57(22)
Insurance (n, %) *									
Commercial	1 (8)	17 (25)	17 (52)	29 (46)	6 (43)	14 (67)	4 (67)	17 (45)	105 (41)
Medicaid	12 (92)	51 (75)	14 (42)	31 (49)	5 (36)	5 (24)	1 (17)	19 (50)	138 (54)
Other	0	0	2 (6)	3 (5)	3 (21)	2 (10)	1 (17)	2 (5)	13 (5)

^aBMI is body mass index.

* Data points missing

Table 4 (online only). Pharmacologic Therapies Administered Prior to Intubation by Site

	Site 1 N=13	Site 2 N=68	Site 3 N=33	Site 4 N=65	Site 5 N=15	Site 6 N=21	Site 7 N=6	Site 8 N=40	All N=261
	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>
Albuterol									
Inhaled, intermittent	8 (62)	59 (87)	23 (70)	48 (74)	10 (67)	15 (71)	3 (50)	31 (78)	197 (75)
Inhaled, continuous	7 (54)	24 (35)	18 (55)	27 (42)	7 (47)	10 (48)	4 (67)	21 (53)	118 (45)
Corticosteroids, IV ^a or oral	9 (69)	50 (74)	22 (67)	42 (65)	11 (73)	13 (62)	4 (67)	29 (73)	180 (69)
Ipratropium, Inhaled	5 (38)	37 (54)	13 (39)	13 (20)	8 (53)	7 (33)	3 (50)	7 (18)	93 (36)
Terbutaline									
IV	3 (23)	5 (7)	16 (48)	19 (29)	1 (7)	6 (29)	2 (33)	3 (8)	55 (21)
SC ^b or IM ^c	1 (8)	4 (6)	1 (3)	4 (6)	1 (7)	1 (5)	0	2 (5)	14 (5)
Inhaled	1 (8)	0	0	0	0	0	0	0	1 (0.4)
Isoproterenol, IV	1 (8)	0	0	1 (2)	0	0	0	0	2 (1)
Epinephrine									
IV	0	6 (9)	4 (12)	2 (3)	0	0	1 (17)	4 (10)	17 (7)
SC or IM	1 (8)	37 (54)	12 (36)	35 (54)	6 (40)	3 (14)	0	9 (23)	103 (39)
Inhaled	1 (8)	0	4 (12)	9 (14)	2 (13)	0	0	5 (13)	21 (8)
Atropine, IV	1 (8)	7 (10)	4 (12)	11 (17)	0	2 (10)	0	3 (8)	28 (11)
Aminophylline/Theophylline IV or oral	1 (8)	1 (1)	0	1 (2)	2 (13)	1 (5)	1 (17)	4 (10)	11 (4)
Helium-Oxygen, Inhaled	0	4 (6)	2 (6)	14 (22)	3 (20)	1 (5)	0	8 (20)	32 (12)
Magnesium sulfate, IV	4 (31)	30 (44)	18 (55)	34 (52)	5 (33)	9 (43)	2 (33)	16 (40)	118 (45)
Ketamine, IV	1 (8)	0	5 (15)	3 (5)	1 (7)	3 (14)	3 (50)	2 (5)	18 (7)

^a IV is intravenous; ^b SC is subcutaneous; ^c IM is intramuscular

Table 6 (online only). Pharmacologic Therapies Administered After Extubation by Site

	Site 1 N=13	Site 2 N=66	Site 3 N=32	Site 4 N=62	Site 5 N=15	Site 6 N=17	Site 7 N=6	Site 8 N=40	All N=251
	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>	<i>n (%)</i>
Albuterol									
Inhaled, intermittent	12 (92)	63 (95)	29 (91)	61 (98)	15 (100)	15 (88)	6 (100)	38 (95)	239 (95)
Inhaled, continuous	3 (23)	34 (52)	9 (28)	19 (31)	4 (27)	4 (24)	3 (50)	23 (58)	99 (39)
Corticosteroids, IV ^a or oral	8 (62)	61 (92)	32 (100)	52 (84)	10 (67)	16 (94)	5 (83)	37 (93)	221 (88)
Ipratropium, Inhaled	7 (54)	42 (64)	15 (47)	5 (8)	6 (40)	15 (88)	4 (67)	17 (43)	111 (44)
Terbutaline									
IV	3 (23)	4 (6)	10 (31)	8 (13)	0	4 (24)	1 (17)	1 (3)	31 (12)
SC ^b or IM ^c	0	0	0	1 (2)	0	1 (6)	0	0	2 (1)
Inhaled	0	0	0	0	0	0	0	0	0
Isoproterenol, IV	1 (8)	0	0	0	0	0	0	0	1 (0.4)
Epinephrine									
IV	0	0	2 (6)	1 (2)	0	0	0	1 (3)	4 (2)
SC or IM	0	2 (3)	0	3 (5)	0	0	0	0	5 (2)
Inhaled	1 (8)	2 (3)	6 (19)	6 (10)	6 (40)	0	0	1 (3)	22 (9)
Atropine, IV	0	0	0	0	0	0	0	0	0
Aminophylline/Theophylline IV or oral	4 (31)	3 (5)	0	0	1 (7)	1 (6)	2 (33)	2 (5)	13 (5)
Helium-Oxygen, Inhaled	0	12 (18)	0	15 (24)	4 (27)	0	0	20 (50)	51 (20)
Magnesium sulfate, IV	0	5 (8)	3 (9)	4 (6)	0	0	0	3 (8)	15 (6)
Ketamine, IV	1 (8)	0	2 (6)	4 (6)	0	1 (6)	0	1 (3)	9 (4)

^a IV is intravenous; ^b SC is subcutaneous; ^c IM is intramuscular

Figure 2 (online only). Overall Distribution of Length of Mechanical Ventilation in Survivors